Addressing obesity in primary care remains a significant challenge, despite established evidence-based strategies and the introduction of new anti-obesity medications. Obstacles such as weight bias, stigma, and limited patient engagement in shared decision-making complicate effective weight management. With the growing array of therapeutic options for obesity, it is crucial for clinicians to adopt shared decision-making practices to improve treatment adherence, support patient goals, and foster holistic, patient-centered care.
Join our engaging 3-part on-demand Community Collective Chapter Series, Overcoming Obesity: A PCP’s Guide to Comprehensive Obesity Care. This series, in collaboration with local AAFP Chapter meetings, equips learners with evidence-based approaches to screening, diagnosing, and treating obesity. Gain practical strategies for initiating weight management conversations with patients, incorporating shared decision-making to personalize treatment goals.
Don’t miss this opportunity! Enroll now to gain valuable insights and elevate your practice in obesity care.
Speakers
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor and Diabetologist
Department of Clinical Sciences and Community Health
Touro University California College of Osteopathic Medicine
Vallejo, CA, USA
Jay H. Shubrook, DO is a Board-Certified family physician and a Fellowship trained Diabetologist. He is a Professor at Touro University California where he also serves as the Director of Diabetes Services. His research focus is on the prevention and early intervention for type 2 diabetes. His clinical and professional focus is on better training the primary care workforce to be prepared to help people manage diabetes. He is the Associate Editor of Clinical Diabetes and is the Chair of the Board of the American College of Diabetology. He was honored to serve on the AGA steering and writing committee for the NASH: A call to action guidelines for evaluation and treatment of NASH.
Martin J. Abrahamson, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Boston, MA, USA
Martin J. Abrahamson, MD, is associate professor of medicine at Harvard Medical School, director of the Division of Continuing Medical Education in the Department of Medicine, and an active faculty member of the Endocrine Division, Department of Medicine at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He received his medical degree from University of Cape Town in South Africa and completed his internship, residency, and clinical fellowship in internal medicine and endocrinology at Groote Schuur Hospital in Cape Town, where he was a research fellow before joining the faculty of medicine at the University of Cape Town and Groote Schuur Hospital. Dr. Abrahamson was joint head of the Endocrine Unit in Cape Town before taking up a faculty appointment at Harvard Medical School and Beth Israel Hospital in 1992. He joined the faculty at Joslin Diabetes Center in 1998, where he held positions as Chief of Adult Diabetes, Chief Medical Officer, and Senior Vice President for Medical Affairs until 2015. While at Joslin Diabetes Center, Dr. Abrahamson led the reorganization of the Adult Diabetes Section into multidisciplinary teams comprised of physicians, nurse practitioners, nurse educators, nutritionists, and exercise physiologists and spearheaded “pathways of care” for patients referred to Joslin (JoslinCare). He has co-authored guidelines for the pharmacological and perioperative management of patients with diabetes and management of hyperglycemic emergencies and authored more than 80 papers, review articles, and chapters related to diabetes. Dr. Abrahamson’s research interests include the management of patients with diabetes and use of technology to improve diabetes care and outcomes. Dr. Abrahamson is board certified in endocrinology, diabetes and metabolism and is a fellow of the College of Physicians of South Africa. He has been cited regularly in Boston Magazine as one of Boston’s top doctors, and he has delivered numerous invited lectures nationally and internationally on the management of diabetes. In 2010, he was the recipient of the Samuel Eichold II Memorial Award for contributions to Diabetes from the American College of Physicians.
Robert Kushner, MD, MS
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL, USA
Robert Kushner, MD, MS is Professor of Medicine and Medical Education at Northwestern University Feinberg School of Medicine, and Director of the Center for Lifestyle Medicine in Chicago, IL, USA. After finishing a residency in Internal Medicine at Northwestern University, he went on to complete a postgraduate fellowship in Clinical Nutrition and earned a Master’s degree in Clinical Nutrition and Nutritional Biology from the University of Chicago, IL, USA. Dr Kushner is past President of The Obesity Society, the American Society for Parenteral and Enteral Nutrition, and the American Board of Physician Nutrition Specialists (ABPNS), and a founder and first Chair of the American Board of Obesity Medicine (ABOM). Dr Kushner has authored over 250 original articles, reviews, books and book chapters covering medical nutrition, medical nutrition education and obesity, and is an internationally recognised expert on the care of patients with overweight or obesity issues. He is author/editor of multiple books; current books include Nutrition and Bariatric Surgery (CRC Press, 2015), Lifestyle Medicine: A Manual for Clinical Practice (Springer, 2016), Creating a Lifestyle Medicine Center (Springer, 2020), Six Factors to Fit – Weight Loss that Works for You! (Eat Right Press, 2020), and Primary Care: Evaluation and Management of Obesity (Wolters Kluwer, 2022).
Matthea Rentea, MD
Internal Medicine Board Certified, ABOM Diplomate
Owner, The Rentea Metabolic Clinic
Indianapolis, IN, USA
Board-certified Internal Medicine physician with 10 years’ experience providing patient centered high-quality care to medically complex patients. Expertise in obesity medicine with a diplomate from the American Board of Obesity Medicine. Owner of the Rentea Metabolic Clinic, a direct specialty care telehealth clinic, focusing on 4 pillar obesity medicine.
Accreditation and Disclosure Information
Target Audience
U.S. primary care physicians, NPs, and PAs including those who are community-based, practice in large ACOs; in rural communities; and who serve patients in underserved areas.
Educational Objective
After completing this CE activity, the participant should be better able to:
- Integrate evidence-based approaches to diagnose, manage, and treat obesity, such as BMI, waist circumference, body fat percentage, and routine visits, especially in patients with concurrent comorbidities.
- Determine appropriate treatment with consideration on the latest clinical evidence, mechanism of action, side effects, drug administration frequency, and patient-specific factors when developing individualized treatment plans for patients with obesity.
- Employ shared decision-making and multidisciplinary approaches when discussing weight management strategies, including treatment and lifestyle modifications, to support optimal adherence and outcomes for patients with overweight/obesity.
Agenda
- Chapter 1: Addressing the Weight of the Matter: Diagnosing Obesity
- Address misconceptions, underdiagnosis, and undertreatment of obesity in primary care settings, including stigma/weight bias, time constraints, provider comfort in the treatment landscape, and patient resistance.
- Review the clinical treatment guidelines in obesity care, including appropriate adiposity measures, such as BMI and waist circumference, to diagnosis obesity
- Examine the complexity of obesity and its interconnection with associated comorbidities
- Chapter 2: No One- Size-Fits-All Approach: Individualizing Obesity Treatment
- Conceptualize system-, provider-, and patient-level barriers that impact treatment initiation, adherence, and meeting weight loss targets/goals
- Evaluate the latest clinical evidence of the evolving treatment landscape of obesity, including new and emerging anti-obesity medications
- Integrate new and emerging anti-obesity medicines into clinical practice
- Chapter 3: Best Practices in Shared Decision-Making (SDM) to Enhance Patient Outcomes
- Strategies to ensure treatment choices are based on collaboration with patients
- Address and provide strategies to barriers that impact patient engagement in obesity care, including weight bias and social determinants of health
- Foster interprofessional collaboration with obesity experts and PCP through shared learning of resources and skills for their patients with obesity
This activity is provided by MLI
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc. (MLI) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
AAFP CME Credit
The AAFP has reviewed Overcoming Obesity: A PCP's Guide to Comprehensive Obesity Care and deemed it acceptable for up to 1.50 Enduring Materials, Self-Study AAFP Prescribed credit(s). Term of Approval is from 09/01/2024 to 08/31/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity..
PA
Medical Learning Institute Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until August 31, 2025. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.5 contact hours and 0.37 contact hours in the area of pharmacology.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
Support Statement
This activity is supported by an educational grant from Lilly.
Disclosure & Conflict of Interest Policy
Medical Learning Institute Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Jay H. Shubrook, DO, FAAFP, FACOFP
Professor and Diabetologist
Department of Clinical Sciences and Community Health
Touro University California College of Osteopathic Medicine
Vallejo, CA, USA
Jay H. Shubrook, DO, FAAFP, FACOFP has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Abbott, Bayer, Eli Lilly, Madrigal, Novo Nordisk
The following relationships have ended within the last 24 months:
Consultant/Advisor: Nevro (ended 6/2023)
Planner/Presenter
Martin J. Abrahamson, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Director, Division of CME
Beth Israel Medical Center
Boston, MA, USA
Martin Julian Abrahamson, MD, FACP, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
Planner/Presenter
Robert F. Kushner, MD, MS
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL, USA
Robert F. Kushner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: Altimmune, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Regeneron, Structure, Weight Watchers
Planner/Presenter
Matthea Rentea, MD
Internal Medicine Board Certified, ABOM Diplomate
Owner, The Rentea Metabolic Clinic
Indianapolis, IN, USA
Matthea Rentea, MD, has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at mvu@mlieducation.org.
For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
About This Activity
Medical Learning Institute Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by an educational grant subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute Inc. | All Rights Reserved
Resources
Chapter 1 Resources
- Slides
- Transcript
- Obesity Staging and Treatment Guidelines
- Primary Care Professionals: Patient Assessment
Chapter 2 Resources
- Slides
- Transcript
- Medicare & Medicaid Coverage of GLIP Agonists for Treatment of Obesity
- Weight Loss Required for Therapeutic Benefit
- Incretin and Pharmacologic Management of Obesity and Associated Comorbidities
- Concomitant Pharmacotherapy: Impact on Body Weight
- Managing Side Effects of Dual GIP/GLP-1 RAs
Chapter 3 Resources